DEF: Utah Medical Products Faces Director Transition, Seeks Stockholder Approval on Key Proposals

Utah Medical Products (UTMD) is set to hold its 2025 Annual Meeting of Stockholders, focusing on the election of a new director, ratification of the accounting firm, and an advisory vote on executive compensation.

Summary

• Utah Medical Products, Inc. (UTMD) will hold its Annual Meeting of Stockholders on May 2, 2025.
• The meeting will address the election of one director, Carrie Leigh, to a three-year term expiring in 2028.
• Stockholders will also vote to ratify the selection of Haynie & Company as the company's independent public accounting firm for the year ending December 31, 2025.
• An advisory vote on the company's executive compensation program will also take place.
• The Board of Directors recommends voting FOR the nominated director, FOR ratification of Haynie & Company, and in support of the executive compensation program.
• Only stockholders of record as of March 3, 2025, are entitled to vote.
• The proxy statement was first furnished to stockholders on approximately April 11, 2025.
• Dr. Barbara Payne is not standing for re-election after 27 years of service.
• The Board of Directors temporarily expanded the Board of Directors in late 2024 to six members in order to appoint Carrie Leigh with some overlap until the end of Dr. Payne's term.
• The number of directors will return to five members after the election.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights positive historical performance and board recommendations, it also acknowledges challenges such as lower earnings and a recent stock price decline. The late filing is also a negative.

Positives

• The Board of Directors is recommending votes in favor of all proposals, indicating confidence in the company's direction.
• Executive officers and directors holding approximately 7% of the issued and outstanding stock have indicated their intent to vote in favor of all proposals.
• The company has a clawback policy in place to recover erroneously awarded compensation.
• UTMD stockholder value in terms of share price plus cash dividends paid to stockholders grew 1,183% over the last 26 years to the end of 2024, which outpaced the NASDAQ Composite by 50% and more than doubled the Dow Jones Industrial Average and S&P 500 indices over that same period of time.

Negatives

• UTMD's stock price closed at $61.47 at the end of 2024, which is a low year-end value UTMD has not seen since 2015.
• The annual MB paid to Mr. Cornwell in early 2024 for 2023 performance represented 64% of his total 2024 compensation.
• Mr. Cornwell's 2024 MB was 17% lower than in 2023, the same as the base value for all employees set by the Compensation Committee as a result of the Company's consolidated Earnings Before Tax (and MB accrual) in 2024 which were 17% lower than in 2023.
• Brian Koopman filed a Form 4 on November 8, 2024 that was four days late.

Risks

• Global economic conditions, government restrictions on medical procedures, and the competitive environment could impact the company's performance.
• Product liability exposure and regulatory compliance are ongoing risks.
• The company's future performance is subject to various factors, including the life cycle of products and new product development.
• The company's consolidated Earnings Before Tax (and MB accrual) in 2024 which were 17% lower than in 2023.

Future Outlook

The Board of Directors intends to provide stockholders with an advisory vote on executive compensation every year. Management expects to recommend that additional options be awarded on an annual basis to the Company's key employees based on its belief that sharing ownership of the Company with those who help create its success is the best way to assure growth in stockholder value.

Management Comments

• Kevin L. Cornwell, Chairman & CEO: 'UTMD has always maintained an open invitation for stockholders to call management directly with questions and/or concerns.'
• The Company believes that its compensation policies, in particular its profit-sharing MB program and employee stock option awards, align employee compensation with stockholder interest in creating longer term stockholder value and consistent profitability.

Industry Context

The document references the medical device industry and the importance of maintaining competitive advantages in a consolidating marketplace. It also mentions the ICB: 4537 Medical Supplies index as a peer group for stock performance comparison.

Comparison to Industry Standards

• The document compares UTMD's stock performance to the NASDAQ Composite Total Return and the NASDAQ ICB: 4537 Medical Supplies index.
• UTMD stockholder value in terms of share price plus cash dividends paid to stockholders grew 1,183% over the last 26 years to the end of 2024, which outpaced the NASDAQ Composite by 50% and more than doubled the Dow Jones Industrial Average and S&P 500 indices over that same period of time.

Management Changes

Stakeholder Impact

• Stockholders are asked to vote on key proposals that will impact the company's governance and executive compensation.
• Employees may be impacted by changes in compensation policies and retirement plans.
• The company's performance and risk management strategies will affect its relationships with customers, suppliers, and other stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The Board of Directors and Compensation and Benefits Committee will review the voting results and consider feedback in future decisions about executive compensation.
• The company will continue to monitor and address risks related to economic conditions, regulatory compliance, and product liability.

Key Dates

Keywords

proxy statement, annual meeting, executive compensation, board of directors, stockholders, Haynie & Company, director election, UTMD, Utah Medical Products, governance